The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2025 | A session on the management of treatment lines throughout the course of CLL
In this video, Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, highlights the key takeaways from a session she chaired on the management of treatment lines throughout the course of chronic lymphocytic leukemia (CLL). The session covered topics such as whether cure is possible beyond the frontline setting in CLL, and selecting between continuous versus time-limited treatment options for patients. This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2025 in Krakow, Poland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So we had two excellent presentations on the overview of treatment like, can we cure CLL? If yes, is there any chance for curing the disease later than in frontline? And the answer Jennifer Woyach gave here was no, probably when we really want to cure the disease we have to administer our best treatment in the frontline regimen. And she also raised the question, for example, with cellular treatments, as CAR T-cells, which are not approved in Europe, but in the U...
So we had two excellent presentations on the overview of treatment like, can we cure CLL? If yes, is there any chance for curing the disease later than in frontline? And the answer Jennifer Woyach gave here was no, probably when we really want to cure the disease we have to administer our best treatment in the frontline regimen. And she also raised the question, for example, with cellular treatments, as CAR T-cells, which are not approved in Europe, but in the U.S., does it really make sense to give them as a last line regimen when we know maybe this is a potentially curative treatment, at least in a small minority of the patients.
And what Nitin Jain also evaluated was which patient is suitable for which type of treatment. So the question on continuous treatment versus time-limited treatment and the different choices we have on time-limited treatment. And I think there is, with more studies coming up, a more and more consensus that probably the continuous treatments are better suitable for either very high-risk CLL with TP53 abberation or also elderly frail patients for whom it’s just difficult to do a ramp-up with a BCL2 inhibitor. However, we have to wait for the CLL17 data in order to have here a final answer, with respect also to different time-limited treatments.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
